Genflow Biosciences links ageing science with MASH research

Genflow Biosciences Plc

Metabolic dysfunction-associated steatohepatitis, or MASH, is a progressive liver disease caused by excess fat, inflammation and cellular damage in the liver. It was previously known as nonalcoholic steatohepatitis, or NASH, and forms part of the broader category of metabolic dysfunction-associated steatotic liver disease.

MASH can progress from inflammation to fibrosis, cirrhosis, liver failure and liver cancer. The disease often develops without clear symptoms, which means significant damage may occur before diagnosis. This creates a need for earlier detection, better disease monitoring and treatments that can address the biological processes driving liver deterioration.

The condition is closely associated with metabolic risk factors, including obesity, Type 2 diabetes, insulin resistance, high cholesterol, high triglycerides and high blood pressure. However, it can also affect people who are not overweight. Its causes and progression therefore extend beyond any single risk factor and involve a broader breakdown in metabolic and cellular health.

Genflow Biosciences is developing gene therapies aimed at the biological mechanisms of ageing. Its research is centred on variants of the SIRT6 gene, which is associated with the regulation of cellular repair, metabolism, inflammation and genomic stability.

MASH’s progression involves chronic inflammation, tissue damage and fibrosis, all of which are connected to declining cellular function.

Genflow’s SIRT6-based approach can influence the underlying processes that contribute to liver damage. A therapy capable of improving cellular resilience, regulating inflammation or supporting metabolic function could have applications across several age-related conditions. MASH provides a defined disease setting in which these mechanisms can be studied.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

Genflow Biosciences advances SIRT6 patent portfolio in US and Europe

Genflow Biosciences has reported progress on its SIRT6 patent families, including a published US application and Track One examination.

Genflow Biosciences moves longevity programme towards its next test

Genflow Biosciences has reported better survival rates and no adverse events three months into its ageing-dog gene therapy study.

Genflow Biosciences advances a focused gene therapy pipeline for healthy ageing

Genflow Biosciences is building a focused SIRT6 gene therapy pipeline across human health, veterinary medicine and skin-related applications.

SIRT6 positions Genflow Biosciences in a high-value area of longevity research

Genflow Biosciences is targeting SIRT6 as a potential route to improve DNA repair, metabolic control and healthier ageing.

Genflow Biosciences reports continued SIRT6 progress in first half of 2026

Genflow Biosciences reported positive interim and three-month follow-up results from its SLAB canine trial, expanded animal health partnerships, secured a fully funded LNP collaboration with Acuitas Therapeutics and strengthened its SIRT6 patent portfolio.

Search